Abattis Bioceuticals Corp.
OTCQX : ATTBF
CNSX : ATT

Abattis Bioceuticals Corp.

February 10, 2015 15:00 ET

Abattis Retains J2 Response as a Marketing Partner

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 10, 2015) - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTCQX:ATTBF) (CSE:ATT), a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America, would like to announce that Abattis has retained J2Response as a marketing partner.

After a rigorous search for the right marketing firm for Abattis products, we are pleased to announce selection of J2Response Marketing as our preferred service provider for 2015.

J2 Response is a direct response advertising and marketing agency that offers a full range of marketing and advertising services including radio advertising, print advertising, direct response TV (DRTV) advertising, infomercials, Internet marketing, social media marketing, and others.

"J2 Response brings together the elements that link marketing, merchant processing, fulfillment, design, and more" says Denby Greenslade of Abattis.

"Direct Response marketing is one of the most competitive and technical fields in business today" says Justin Baumann, Co-Founder of J2Response. Justin goes on to say, "Our executive team has one of the most successful track records in direct response marketing in the industry."

"All successful campaigns start with creative insights and design" states Justin Steinle, J2's other Co-Founder. "By studying Abattis ' brand elements, our design team is able to distill product benefits into a coherent message and embed these within the marketing message in an engaging and persuasive way. We use the most powerful design tools to convey the Abattis message and product capabilities."

"From an operations stand point it makes sense to have a relationship with a product marketing firm, that has expertise and the staff for direct sales initiatives. J2 Response has a staff that will complement our near term and mid term sales initiatives"

Abattis is using our partnership with J2 Response to support marketing and distribution of our Hemp-based products directly to physicians and licensed healthcare providers. Additionally, J2 Response will support Abattis in Direct Response marketing, Direct Sales efforts as well as Retail distribution. J2 Response will provide outsourced solutions in marketing and advertising campaigns, call center management, telemarketing, customer service, order management, fulfillment and merchant account processing. This will streamline our internal processes, allowing us to focus on our core business.

About Abattis Bioceuticals Corp.

Abattis is a specialty biotechnology company with capabilities through its wholly-owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal markets in North America. The Company is positioned to capitalize on the fast growing trend toward marijuana legalization in the United States and for medicinal use in Canada and international jurisdictions, by supplying and partnering with companies to employ its mass cultivation systems, extraction equipment/technology, and strategic marketing support to licensed growers. The Company also has an extensive pipeline of high-quality products and intellectual property for the rapidly expanding botanical drug market. We follow strict standard operating protocols, and adhere to the applicable laws of Canada and foreign jurisdictions. For more information, visit the Company's website at: .

ON BEHALF OF THE BOARD

Bill Fleming, CEO

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD LOOKING INFORMATION

This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company's Management's Discussion and Analysis under the Company's profile on www.sedar.com. While the Company may elect to, it does not undertake to update this information at any particular time.

Contact Information